In the invention is provided a polypeptide comprising at least 75 amino acids and having an amino acid sequence having at least 90%%, such as at least 95%, 96%, 97, 98%, or 99%, such as 100% sequence identity (%SI) with human Angiotensin- converting enzyme 2 (ACE2) (SEQ ID NO 1), for use in the treatment of COVID19, SARS, or MERS, characterized in that the polypeptide is administered pulmonary and/or nasally. Further is provided the polypeptide for use in reducing the number of active virus particles being exhaled by a treated subject infected by SARS-CoV-2, SARS-CoV, or Mers-CoV. Also a dry powder or an aerosol comprising the polypeptide.
展开▼
机译：在本发明中提供了包含至少75个氨基酸的多肽，并具有至少90 %%的氨基酸序列，例如至少95％，96％，97,98％或99％，例如100％序列 具有人血管紧张素转换酶2（ACE2）（SEQ ID NO 1）的同一性（％Si），用于治疗Covid19，SARS或MERS，其特征在于，所述多肽被施用肺和/或鼻腔。 进一步提供了用于减少由SARS-COV-2，SARS-COV或MERS-COV感染的治疗受试者呼出的活性病毒颗粒的数量的多肽。 也是一种干粉或包含多肽的气溶胶。
展开▼
